Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

A Miriam Hospital researcher has joined forces with international colleagues to call for new strategies to better manage and improve assessment and treatment for hepatitis C (HCV) infection in individuals who inject drugs.

26 Jul 2013

Combination treatment can reduce hepatitis C infection in people who inject drugs

The burden of liver disease could be dramatically reduced by scaling up the combination of interventions for hepatitis C infection among people who inject drugs according to University of Bristol researchers. The findings, published today [24 July], form part of new global recommendations on treating the virus.

25 Jul 2013

WHO urges governments to act against five hepatitis viruses that cause severe liver infections

On World Hepatitis Day (28 July), the World Health Organization (WHO) is urging governments to act against the five hepatitis viruses that can cause severe liver infections and lead to 1.4 million deaths every year. Some of these hepatitis viruses, most notably types B and C, can also lead to chronic and debilitating illnesses such as liver cancer and cirrhosis, in addition to loss of income and high medical expenses for hundreds of millions of people worldwide.

24 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Researchers develop new model for more equitable allocation of livers for transplantation

Using the same type of mathematical formulas used to draw political redistricting maps, Johns Hopkins researchers say they have developed a model that would allow for the more equitable allocation of livers from deceased donors for transplantation.

12 Jul 2013

Nerves play critical role in development and spread of prostate tumors, say researchers

Researchers at Albert Einstein College of Medicine of Yeshiva University have found that nerves play a critical role in both the development and spread of prostate tumors. Their findings, using both a mouse model and human prostate tissue, may lead to new ways to predict the aggressiveness of prostate cancer and to novel therapies for preventing and treating the disease. The study published online today in the July 12 edition of Science.

12 Jul 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

Research reveals link between elevated BMI and increased risk of gallstone in women

New research reveals a causal association between elevated body mass index (BMI) and increased risk of gallstone disease. Results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show women are at greater risk of developing gallstones.

12 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Continental Who's Who recognizes Douglas M. Weissman as a Pinnacle Professional

Dr. Douglas M. Weissman, MD, FACP is recognized by Continental Who's Who as a Pinnacle Professional in the field of Medicine. As a gastroenterologist in private practice since 1993, Dr. Weissman specializes in the treatment of all gastrointestinal, biliary and liver disease problems.

6 Jul 2013

State highlights: Docs prescribe narcotics too often, CDC chief says; Fla. hospices get close scrutiny; Calif. Medi-Cal provider rate bump delayed

The nation's top public health official on Tuesday sharply criticized the widespread treatment of aches and pains with narcotics, saying that doctors are prescribing such drugs too soon, too often and for too long -- putting patients at risk of addiction and overdose. Dr. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, said that doctors are relying on these powerful drugs to treat chronic pain when physical therapy, exercise and other remedies would be safer and in many cases more effective (Girion and Glover, 7/2).

4 Jul 2013

First Edition: July 3, 2013

Today's headlines detail the Obama administration announcement that it would delay the health law rule requiring businesses provide insurance to workers.

3 Jul 2013

Nearly half a million dollars given to physicians working to cure psoriatic diseases

Twelve residents and medical students each received a one-year, $40,000 National Psoriasis Foundation fellowship to study psoriasis and psoriatic arthritis.

3 Jul 2013

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.

2 Jul 2013

Study reveals circadian disruption is a risk factor in alcoholic liver disease

Thirty percent of severe alcoholics develop liver disease, but scientists have not been able to explain why only a subset is at risk. A research team from Northwestern University and Rush University Medical Center now has a possible explanation: disrupted sleep and circadian rhythms can push those vulnerable over the edge to disease.

2 Jul 2013

Study: More people are being affected by drug-induced liver injury than ever before

More people are being affected by drug-induced liver injury (DILI) than ever before, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

27 Jun 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

New study shows that dietary fructose causes liver damage even without weight gain

The role of dietary fructose in the development of obesity and fatty liver diseases remains controversial, with previous studies indicating that the problems resulted from fructose and a diet too high in calories.

20 Jun 2013

New technique offers potential to screen patients for viruses

In research published in Biochemical and Biophysical Research Communications, Saint Louis University researchers describe a technology that can detect new, previously unknown viruses. The technique offers the potential to screen patients for viruses even when doctors have not identified a particular virus as the likely source of an infection.

18 Jun 2013

Liver Disease News and Research

Further Reading

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

Combination treatment can reduce hepatitis C infection in people who inject drugs

WHO urges governments to act against five hepatitis viruses that cause severe liver infections

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Researchers develop new model for more equitable allocation of livers for transplantation

Nerves play critical role in development and spread of prostate tumors, say researchers

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Research reveals link between elevated BMI and increased risk of gallstone in women

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Continental Who's Who recognizes Douglas M. Weissman as a Pinnacle Professional

State highlights: Docs prescribe narcotics too often, CDC chief says; Fla. hospices get close scrutiny; Calif. Medi-Cal provider rate bump delayed

First Edition: July 3, 2013

Nearly half a million dollars given to physicians working to cure psoriatic diseases

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Study reveals circadian disruption is a risk factor in alcoholic liver disease

Study: More people are being affected by drug-induced liver injury than ever before

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

New study shows that dietary fructose causes liver damage even without weight gain

New technique offers potential to screen patients for viruses

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News